The results presented in this study indicated that neurosurgeons may need to change how they approach tumor removal and, when safe, include non-contrast-enhancing tumor during resection to achieve maximal resection.
These results could present an opportunity to broaden inclusion criteria on clinical trials and intensify chemoradiotherapy treatments.
A perioperative study confirmed brain penetrance and robust biomarker suppression in patients with low-grade glioma with an IDH1 mutation.
Using RNA sequencing for individual pediatric cancer cases could more effectively target gene expression in tumors.
Researchers recently looked at differences in survival time between patients with grade II and grade III spinal meningioma.
There could be a new way to diagnose brain tumors earlier.
Investigators assessed effects of TIB on cell number, migration, invasion, estrogen, and progesterone receptor activity and content.
A new study offers hope in predicting glioblastoma responses to chemotherapy, radiation, and combination therapy.
Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma
Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.
Cancer Network spoke with Dr. Shulin Li about his team’s research on the role of the FGL2 protein in glioblastoma immune evasion and tumor progression.